Combined expertise in neurosurgery, engineering, BCI research, and med-device product development will shape the clinical strategy for advanced neurotech platform
AUSTIN, TX / ACCESS Newswire / April 17, 2025 / Paradromics Inc., a neurotechnology company developing the highest data-rate brain-computer interface (BCI) platform, today announced the appointment of Dr. Stephen Ryu as Chief Medical Officer (CMO). Dr. Ryu, a board certified neurosurgeon, is the Chair of Neurosurgery at the Palo Alto Medical Foundation and holds adjunct professorships in Electrical Engineering and Neurosurgery at Stanford University. Dr. Ryu has been a key figure in the Stanford Neuroprosthetics Laboratory for over two decades and has co-authored over 80 peer-reviewed BCI publications.
As CMO, Dr. Ryu will guide clinical decisions related to research, product design, and the healthcare ecosystem as Paradromics advances its first product, Connexus® BCI, through the FDA approval process and into commercialization. "I've been approached by other BCI companies, but I wasn't confident they could deliver," said Dr. Ryu. "Paradromics stood out as the company most likely to succeed - and to do so soon - thanks to its exceptional team and foundational neurotech platform."
Connexus is a high data-rate, long-lasting BCI platform designed to initially restore communication for people with severe motor impairments caused by conditions like ALS, brainstem stroke, and spinal cord injury. Connexus records neural activity at the level of individual neurons and uses advanced artificial intelligence to translate brain signals into speech and text.
"Stephen Ryu is the neurosurgeon who taught many of today's most influential BCI neurosurgeons and neuroscientists how to implant intracortical BCIs," said Matt Angle, Ph.D., founder and CEO of Paradromics. "His decision to join Paradromics signals something bigger than just a team win-it signals maturity of the BCI field. We're moving beyond research and beginning to attract top-tier, clinically-driven leaders who want to build real products that help people in real numbers."
About Paradromics
Paradromics is building the industry-leading brain-computer interface (BCI) platform. Its advanced neurotechnology captures brain activity at the highest resolution, the individual neuron. This rich brain data lays the foundation for boundless AI-enabled treatments for motor impairment, chronic pain, addiction, depression, and other mental health conditions. Paradromics' first clinical product, Connexus® BCI, is designed to help people unable to speak due to debilitating motor conditions communicate independently through digital devices. For more information, visit www.paradromics.com or contact media@paradromics.com.
SOURCE: Paradromics
View the original press release on ACCESS Newswire
